NCT05884255 2026-04-17An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.Jiangsu HengRui Medicine Co., Ltd.Phase 3 Recruiting220 enrolled